Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Open accessThe DOI matches its Crossref record; 134 of the 141 references it cites were found in a registry or an index; 90 of the 190 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients with diabetes that has become available since the past reviews of this subject by the American Diabetes Association and The Endocrine Society and to provide guidance about how this new information should be incorporated into clinical practice. PARTICIPANTS: Five members of the American Diabetes Association and five members of The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair, who is a member of both, to participate in a planning conference call and a 2-day meeting that was also attended by staff from both organizations. Subsequent communications took place via e-mail and phone calls. The writing group consisted of those invitees who participated in the writing of the manuscript. The workgroup meeting was supported by educational grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes Association from Sanofi. The sponsors had no input into the development of or content of the report. EVIDENCE: The writing group considered data from recent clinical trials and other studies to update the prior workgroup report. Unpublished data were not used. Expert opinion was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved by group discussion during conference calls and face-to-face meetings, as well as by iterative revisions of the written document. The document was reviewed and approved by the American Diabetes Association's Professional Practice Committee in October 2012 and approved by the Executive Committee of the Board of Directors in November 2012 and was reviewed and approved by The Endocrine Society's Clinical Affairs Core Committee in October 2012 and by Council in November 2012. CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
Overview
CoChat Summary
TL;DR
This ADA/Endocrine Society workgroup report updates definitions, risks, and prevention strategies for hypoglycemia in diabetes, with a strong emphasis on avoiding severe episodes and hypoglycemia unawareness. It argues for individualized glycemic targets, better monitoring and education, and further research on outcomes, measurement, and new therapies.
Key findings
- The workgroup defines iatrogenic hypoglycemia as all episodes of abnormally low plasma glucose that expose the person to potential harm, and recommends an alert value of ≤70 mg/dL (≤3.9 mmol/L) for patients at risk; it also classifies episodes as severe, documented symptomatic, asymptomatic, probable symptomatic, or pseudo-hypoglycemia.
- Severe hypoglycemia rates reported in the paper ranged from 115 to 320 per 100 patient-years in type 1 diabetes and 35 to 70 per 100 patient-years in type 2 diabetes; because type 2 diabetes is more common, most hypoglycemia episodes occur in people with type 2 diabetes.
- In ACCORD, intensive glycemic control produced threefold higher hypoglycemia and a 20% increase in mortality; post hoc analyses in ACCORD found severe hypoglycemia had a hazard ratio of 1.41 (95% CI 1.03–1.93) for death.
- In hospitalized patients, one retrospective study found 10.5% of 31,970 general-ward admissions had at least one hypoglycemic episode (≤70 mg/dL), and severe hypoglycemia (≤50 mg/dL) was associated with increased length of stay and greater odds of inpatient death and death within 1 year of discharge.
Methods
- This is a workgroup report/consensus document, not an experimental study; five ADA and five Endocrine Society experts were invited, held a planning call and a 2-day meeting, and developed the manuscript through discussion and iterative revisions.
- The group reviewed recent clinical trials and other studies published since the prior reports; unpublished data were not used, and some conclusions relied on expert opinion.
- Consensus was reached by group discussion and was reviewed/approved by both organizations’ committees in October and November 2012.
Limitations
- The paper states that unpublished data were not used, and that expert opinion was used to develop some conclusions.
- The text makes evident that some evidence is observational, post hoc, or limited by small studies, so causal inference is uncertain in several areas (e.g., mortality, cognition); this is an inference from the paper’s cited evidence, not a limitation explicitly stated in one place.
- The paper explicitly notes gaps in knowledge on hypoglycemia outcomes, mechanisms, and prevention, indicating that several recommendations are based on incomplete evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 5 Not valid · 33 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“There is convincing evidence that formal training programs that teach patients to replace insulin “physiologically” by giving background and mealtime/correction doses of insulin can reduce the risk of severe hypoglycemia.”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > What strategies are known to prevent hypoglycemia, and what are the clinical recommendations for those at risk for hypoglycemia? > Patient education
What the sources say
- Supportedcites [100] Mühlhauser, 2002, Patient education—evaluation of a complex intervention, Diabetologia source
The Modelling section describes a structured programme teaching patients to adjust insulin doses, using NPH insulin twice daily and regular insulin before meals. The Long-term implementation section reports decreased rates of severe hypoglycaemia in patients with Type I diabetes and says several prospective studies observed that reduction. The paper supports that such programmes can reduce the risk, although not every evaluation found a reduction. (LLM, conf=0.90)
- Partly supportedcites [101] Bott, 1997, Intensified insulin therapy and the risk of severe hypoglycaemia, Diabetologia sourceExperimental — accuracy not yet measured
The Subjects and methods passage describes structured training in background and mealtime insulin dosing, with patients adjusting doses for glucose and carbohydrate intake. The Results and Discussion report fewer severe hypoglycaemic episodes after the programme, but describe the reduction as an association; they do not establish that training itself caused it. The claim’s description of this as convincing evidence that the programmes can reduce risk is therefore stronger than the paper’s finding. (LLM, conf=0.84)
- Supportedcites [102] Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study, Diabetologia source
The Subjects and methods section describes a structured course teaching background insulin injections and meal-by-meal dose adjustments based on blood glucose and carbohydrate intake. The Abstract reports that severe hypoglycaemia fell from 0.37 to 0.14 events per patient per year after training among people with type 1 diabetes. (LLM, conf=0.92)
- Disputedcites [103] DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ sourceExperimental — accuracy not yet measured
The skills course section describes training patients to adjust insulin to their meals. But the paper reports that severe hypoglycaemia remained unchanged; the Discussion says there was no significant increase, not a reduction in risk. The claimed risk reduction is therefore contrary to the reported finding. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [104] McIntyre, 2010, Dose adjustment for normal eating (DAFNE)—an audit of outcomes in Australia, Med J Aust source
- Partly supportedcites [105] Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (pages not provided) report fewer severe hypoglycemia episodes after DAFNE, a structured education program for adults with type 1 diabetes. The paper describes adjusting insulin to carbohydrate intake, but does not specify the claimed background and mealtime/correction-dose teaching. Its evidence is also a retrospective audit based on self-reported hypoglycemia, which qualifies the claim of ‘convincing evidence.’ (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12)”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion states that after an episode of hypoglycemia, the authors found elevated glycemic thresholds for neurogenic and neuroglycopenic symptoms, including in patients with IDDM in the present study. Its terminology indicates that an elevated threshold means symptoms occur at a lower plasma glucose concentration. The Results also report reduced symptom responses after antecedent hypoglycemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In critical care units, where the accuracy of POC meters is particularly crucial, their performance may be compromised by medications (vasopressors, acetaminophen), treatments (oxygen), and clinical states (hypotension, anemia) (17).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported? > The challenge of measuring glucose accurately
What the sources say
- Partly supportedcites [17] Klonoff, 2011, Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Section 1.1 Evidence says supplemental oxygen can cause falsely low readings with glucose-oxidase meters and identifies acetaminophen, pressor use, and hypotension as potential concerns for POC testing in critically ill patients. It also reports an accuracy discrepancy among patients with hypotension or pressor treatment. The cited passages do not address anemia as a cause of compromised meter performance. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A single threshold value for plasma glucose concentration that defines hypoglycemia in diabetes cannot be assigned because glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12) and to higher plasma glucose concentrations in patients with poorly controlled diabetes and infrequent hypoglycemia”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion (p. 823) reports that antecedent hypoglycemia changes the glycemic threshold for symptoms in patients with insulin-dependent diabetes. The Discussion also reports symptoms at higher plasma glucose concentrations in patients with poorly or moderately controlled diabetes. Together, these findings support the claim that no single symptom-based plasma glucose threshold applies across these circumstances. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
- Not checked — no full text of the sourcecites [13] Boyle, 1988, Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hypoglycemia puts patients at risk for injury and death.”
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
“There is no doubt that hypoglycemia can be fatal (26).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Supportedcites [26] Cryer, 2011, Death during intensive glycemic therapy of diabetes: mechanisms and implications, Am J Med source
In the main text (page unavailable), Cryer states that iatrogenic hypoglycemia causes recurrent morbidity in people with diabetes and is sometimes fatal. This supports the broad claim that hypoglycemia puts these patients at risk of harm and death. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
76 more claims · 43 with their cited sources checked
Create a free account to see all 104 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial hyperglycemia and resultant compensatory hyperinsulinemia from high dietary glycemic load can lower plasma glucose to concentrations that compromise brain glucose, w70 mg/dL (3.8 mmol/L) (36), triggering the secretion of autonomic counterregulatory hormones such as adrenaline, cortisol, glucagon, and growth hormone (37).”
From High glycemic index diet as a risk factor for depression: analyses from the Women’s Health Initiative (2015) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103-105).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recurrent hypoglycaemia results in an increased likelihood of hypoglycaemia unawareness and subsequent severe hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that triggers the counter-regulatory responses to return to euglycaemia.106”
From Type 1 diabetes (2018) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoglycemia is a frequent and dangerous complication of diabetes (1), causing changes in physiological parameters (2,3).”
From Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Individualized glucose targets, patient education, nutrition intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (94).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [94]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Deakin T McShane CE Cade JE Williams RD Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003417 15846663”
Cited work 10.1002/14651858.cd003417.pub2 · retracted 2015-06-30 · notice 10.1002/14651858.cd003417.pub3 · this paper published 2013-04-13
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In VADT, a recent severe hypoglycemic event was the strongest independent predictor of death at 90 days (3).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 2×
“event of troublesome hypoglycemia (96).”
BackgroundIntensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Research works printed but not linked: 2
- Reno, 2011, Deaths due to severe hypoglycemia are exacerbated by diabetes and ameliorated by hypoglycemic pre-conditioning (Abstract), Diabetes, 60, A81
- Aubert, 1995, Diabetes-Related Hospitalization and Hospital Utilization
Cited by
Items 901–1,000 of 1,392
Martyn-Nemeth, P. A., Birlingmair, R., Idemudia, E., & Park, C. (2019) · Nursing Open · doi:10.1002/nop2.267 · Cited by 5
“Hypoglycaemia, defined as a blood glucose level ≤70 mg/dl (3.9 mM; Seaquist et al., 2013), is a major limiting factor in achieving recommended glycaemic targets.”
BackgroundInfluentialThe pharmacist’s role in continuous glucose monitoring
Isaacs, D. M. (2020) · Pharmacy Today · doi:10.1016/j.ptdy.2020.04.014 · Cited by 5
Xie, X., Guo, J., Bremner, K. E., Wang, M., Shah, B. R., & Volodin, A. I. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0059 · Cited by 5
“It is characterized by low blood glucose levels and can be asymptomatic (biochemical) or symptomatic (mild, moderate or severe) [2,3].”
BackgroundZhang, P., Chen, M., Zhang, H., Luo, Y., Zhu, D., Li, X., Ji, J., Wang, D., Duolikun, N., & Ji, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00892-6 · Cited by 8
“Hypoglycemia was categorized as severe hypoglycemia, documented symptomatic, asymptomatic, probable symptomatic or pseudo-hypoglycemia according to the American Diabetes Association recommendations [22].”
BackgroundThe clinical impact of hypoglycemia in hospitalized patients
Borzì, V., & Fontanella, A. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.2015.549 · Cited by 6
Should a pilot on insulin really fly?
Manen, O., Martel, V., Germa, R., Paris, J., & Perrier, E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70056-7 · Cited by 5
Iglay, K., Qiu, Y., Fan, C. S., Li, Z., Tang, J., & Laires, P. A. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190325 · Cited by 5
Keeping up-to-date with diabetes care and education
Funnell, M. M., & Freehill, K. (2018) · Nursing · doi:10.1097/01.nurse.0000545015.98790.27 · Cited by 5
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.60 · Cited by 6
“Thus, pharmacotherapy of GDM for tight glycaemic control is needed to reduce foetal adverse outcomes (11-13).”
BackgroundA case of severe relapsing sulphonylurea-induced hypoglycaemia
Mifsud, S., Schembri, E. L., & Fava, S. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231368 · Cited by 5
Wing, J., & Jivan, D. (2015) · South African Medical Journal · doi:10.7196/samj.2016.v106i1.10284 · Cited by 6
Brož, J., Žďarská, D. J., Urbanová, J., Brabec, M., Křivská, B., Doničová, V., Štěpánová, R., Martinka, E., & Kvapil, M. (2016) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s103459 · Cited by 5
“The secondary objectives are to determine the incidence of hypoglycemia as per the ADA definitions; 14 determine their causes and methods that the patients use to manage them; determine the frequency of insulin titration, insulin dose adjustments, and adherence to the time schedule of…”
Moreno-Fernández, J., Gómez, F. J., Moreno, M. Á. G., & Castano, J. P. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4171789 · Cited by 5
“Hypoglycemia events and severe hypoglycemia were defined in order to standardize concepts: an event of measured plasma or capillary glucose concentration ≤70mg/dL and any hypoglycemia requiring assistance of another person to actively administer carbohydrates and glucagon or take other corrective actions were used, re…”
MethodPallayová, M., & Breznoščáková, D. (2020) · Endocrine Regulations · doi:10.2478/enr-2020-0015 · Cited by 5
“…of hypoglycemia (“Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia,” 2005; Seaquist et al. 2013) is often characteristic, the combination of deficient glucagon and epinephrine responses particularly in the individuals with…”
BackgroundAssessment procedures including comprehensive geriatric assessment
Valencia, W. M., Danet‐Lamasou, M., Florez, H. J., & Bourdel‐Marchasson, I. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch5 · Cited by 6
Ferhatbegović, L., Bećirović, M., Bečirović, E., Sarajlić, S., Ribić, A., Šarić, A., Bećirović, A., & Pojskić, B. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1765597 · Cited by 5
Wong, C., de Bray, A., Hassan, N. U., Almohandes, A., Thant, K. Z., Gill, S., Gill, D., Forsdick, H., Sinclair, A. J., Karamat, M. A., et al. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241269133 · Cited by 5
“21,22 CGM can play a key role in combating the hypoglycaemia unawareness from impaired counter-regulatory response, by predicting and reducing hypoglycaemia in this population, as demonstrated in the Wireless Innovation in Seniors with Diabetes Mellitus trial with a small but statistically…”
MethodSomers, R. J., Walkinshaw, N., Hierons, R. M., Elliott, D., Iqbal, A., & Walkinshaw, E. (2025) · Software Testing Verification and Reliability · doi:10.1002/stvr.70000 · Cited by 8
Wermund, A. M., Thalheim, T., Medek, A., Schmidt, F., Peschel, T., Strübing, A., Neumann, D., Scherag, A., Loeffler, M., Kesselmeier, M., et al. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000892 · Cited by 4
Rehman, N. U., Contreras, I., Beneyto, A., & Vehí, J. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000996 · Cited by 4
“Additionally, T1D subjects are at risk of hypoglycemia, characterized by low BG levels, which may result from excessive insulin administration, missed meals, or intense physical activity and can lead to severe outcomes such as seizures or loss of consciousness if untreated [8–10].”
Cognitive Performance and Diabetic Retinopathy: What Your Eyes Can Reveal About Your Brain
Faria, A. C. R. D. A., Dall'Agnol, J. F., Gouveia, A. M., Paiva, C. I. D., Segalla, V. C., Ogata, F. E., & Baena, C. P. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220805154638 · Cited by 7
“Severe hypoglycemia was defined as that in which the patient needed help from others for treatment and/or had a decrease in consciousness level, with improvement in symptoms after treatment [27].”
BackgroundMethodAlsharif, A. A., Wong, I. C. K., Ma, T., Lau, W. C. Y., Alhamed, M., Alwafi, H. H., & Wei, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1177636 · Cited by 4
Pancreas Allocation in the Eurotransplant Area
Arbogast, H. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_8 · Cited by 3
Veryanti, P. R., Sauriasari, R., Sartika, R. A. D., & Elya, B. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998280552231228064154 · Cited by 5
“The answers to these questions were analyzed and categorized into the following 5 classifications of hypoglycemia (Table 1 ) [32]: If the patient answers "Yes" to questions number 1 and 3, then the patient is categorized as having severe hypoglycemia.”
BackgroundPathan, M. F., Akter, N., Selim, S., Amin, M. F., Afsana, F., Saifuddin, M., Kamrul-Hasan, A. B. M., Mustari, M., Chakraborty, A. K., & Hossain, R. M. M. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_29_23 · Cited by 5
Dey, A. K., Gokalani, R. A., Kale, M. C., Sankar, P., Saboo, B., Maheshwari, A., Jaggi, S., Jagadeesha, A., Panchal, D., Chawla, M. S., et al. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_121_23 · Cited by 5
Severe hypoglycemia in a diabetic patient with pituitary apoplexy: a case report
Getahun, B. M., Gebeyehu, M. A., Getahun, A. M., et al. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04642-9 · Cited by 4
Takada, H., Matsumura, T., Shimamura, H., Matsui, M., Kon, S., Fukumoto, A., Kubota, T., Yoshida, K., Iwahashi, H., & Takahashi, M. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175252 · Cited by 4
Lin, Y. K., Ye, W., Hepworth, E., Ang, L. P., Amiel, S. A., & Fisher, S. J. (2025) · Diabetic Medicine · doi:10.1111/dme.15513 · Cited by 5
Advances in Basal Insulin Therapy
Goldman, J. D., & White, J. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516667128 · Cited by 4
Puppalwar, G., Sawant, S., Silgiri, B., Shukla, K., & Barkate, H. V. (2017) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2017.74011 · Cited by 6
Home, P. D., Calvi-Gries, F., Blonde, L., Pilorget, V., Berlingieri, J., & Freemantle, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13179 · Cited by 4
“0 mmol/L or prompt recovery after oral carbohydrate, intravenous glucose or intramuscular glucagon.(17) Updated mean HbA1c was the average of HbA1c measurements from 1 month after beginning insulin up to follow-up year values.”
BackgroundFritzen, K., Gutschek, B., Coucke, B., Zakrzewska, K. E., Hummel, M., & Schnell, O. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818758104 · Cited by 4
Diabetes and pregnancy: Risks and opportunities
Lewis, H., Egerman, R. S., Kazory, A., & Sattari, M. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.16138 · Cited by 10
“Hyperglycemia ( Table 1 12,13 ) during the peri-conception period or during pregnancy is believed to be the single most important determinant of adverse outcomes in women with diabetes.”
InfluentialBowering, K., Rodbard, H. W., Russell-Jones, D. L., Bode, B. W., Harris, S. B., Piletič, M., Heller, S. R., Woo, V. C., Babu, V., Dethlefsen, C., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0553-7 · Cited by 4
Self-citationA Systematic Review of Neuroprotective Strategies in the Management of Hypoglycemia
Nistor, M., Schmidt, M., Graul, I., Rakers, F., & Schiffner, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030550 · Cited by 6
“This state of impaired awareness of hypoglycemia (IAH) can, in combination with a defective glucose counter-regulation, lead to hypoglycemia-associated autonomic failure, a vicious cycle that exposes the patient to a 25-fold higher risk of further episodes of hypoglycemia [8,9].”
BackgroundInfluentialRose, L., Kadowaki, T., Pieber, T. R., Buchholtz, K., Ekelund, M., Gorst‐Rasmussen, A., & Philis‐Tsimikas, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0608-4 · Cited by 4
Pollock, R. F., Heller, S. R., Pieber, T. R., Woo, V. C., Gundgaard, J., Hallén, N., Luckevich, M., Tutkunkardas, D., Zinman, B., & On Behalf of the DEVOTE Study Group (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13730 · Cited by 6
“Severe hypoglycaemia was selfrecorded in the DEVOTE trial and was defined according to the American Diabetes Association definition as an event requiring third-party assistance.(25) Non-severe hypoglycaemia was not recorded.”
MethodSelf-citationDepiction of Physiological Homeostasis by Self-Coupled System and Its Significance
Lu, X., Jin, G., Chen, W., Yu, X., & Ling, F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01205 · Cited by 5
for the GOAL_RO Study Group, Stegaru, D., Nicodim, S., Vladu, D., Guțu, O., Onaca, A. G., Pîrvu, F., Moise, M., & Guja, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4533 · Cited by 5
“The 2013 criteria of the ADA/Endocrine Society of hypoglycemia definition were used (17).”
MethodBengtsen, M. B., Knudsen, J. S., Bengtsen, M. B., Møller, N., & Thomsen, R. W. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.227 · Cited by 4
Grassi, B. A., Onetto, M. T., Zapata, Y., Jofré, P., & Echeverría, G. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.03.017 · Cited by 6
Harris, S. B., Ajala, O., Bari, B., Liutkus, J., Hahn, J., Martyn, O., & Zwicker, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01063-5 · Cited by 5
“Severe hypoglycaemia was defined as a reported event requiring the assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions [20].”
BackgroundKramer, G., Kloos, C., Müller, U., Wolf, G., & Kuniß, N. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00700-0 · Cited by 4
“9 mmol/l without typical symptoms [9].”
Salawati, E. M. (2021) · Cureus · doi:10.7759/cureus.17586 · Cited by 6
“Hypoglycaemia can be mild or severe, causing serious complications such as cardiac mortality, dementia, seizures, fall-related fractures and death [6,10-12].”
BackgroundBloomer, K. (2021) · British Paramedic Journal · doi:10.29045/14784726.2021.9.6.2.1 · Cited by 4
“Bloomer, K, British Paramedic Journal 2021, vol. 6(2) 1–9 complications, according to the wider literature (Cryer & Arbelaez, 2017; Seaquist et al., 2013).”
BackgroundStagi, S., Papacciuoli, V., Ciofi, D., Piccini, B., Farello, G., Toni, S., Ferrari, M., & Chiarelli, F. (2021) · Nutrients · doi:10.3390/nu13103517 · Cited by 7
“88 and >10 mmol/L, respectively) were assessed using standard patient diaries [38].”
MethodRole of the Diabetes Educator in Inpatient Diabetes Management
American Association of Diabetes Educators (2018) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721718820944 · Cited by 5
Erukulapati, R. S., Ganguri, M., Menon, A. S., Ayyagari, U., Jayapaul, M. K., Gurazada, K. C., Nalla, S., Srinath, A., Sampath, S. K., Manohar, S. P., et al. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0061 · Cited by 6
Administrative Coding Versus Laboratory Diagnosis of Inpatient Hypoglycemia
Gallo, R. J., Fang, D. Z., & Heidenreich, P. A. (2023) · Diabetes Care · doi:10.2337/dc23-0053 · Cited by 5
Pilla, S. J., Meza, K., Beach, M. C., Long, J. A., Gordon, H. S., Bates, J. T., Washington, D. L., Bokhour, B. G., Tuepker, A., Saha, S. S., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100641 · Cited by 8
“18 However, the effectiveness of this strategy has not been tested and practice change would be needed to integrate this into the primary care work fl ow.”
BackgroundExperimental pharmacological approaches to reverse impaired awareness of hypoglycemia—a review
Hashmi, H. Z., Khowaja, A. A., & Moheet, A. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349004 · Cited by 5
Erukulapati, R. S., Manikandan, R. M., Jakkidi, L. R., Sathyanarayana, S. O., Ayyagari, U., Aswathiah, S., Nalla, S., Sampath, S. K., Manohar, S. P., Shah, S. C., et al. (2024) · Clinical Diabetology · doi:10.5603/cd.98136 · Cited by 7
“At each visit, doctors should assess the person’s risk of hypoglycemia, especially if they are on insulin [53].”
BackgroundSchwartz, S. S., & Herman, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394805 · Cited by 6
Omar, M. A. K., Kok, A., Khutsoane, D., Joshi, S., Ramaboea, M., Mashitisho, M. L. I., Chetty, V., Koopman, L. J., Johnson, L., & on behalf of the IO HAT investigator group (2017) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2017.1385966 · Cited by 4
Thong, E. P., Catford, S. R., Fletcher, J., Wong, P., Fuller, P. J., Teede, H. J., & Milat, F. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0010 · Cited by 4
“Recurrent hypoglycaemic episodes can diminish the sympathoadrenal response and lower the threshold at which symptoms occur (16).”
BackgroundPathan, M. F., Fariduddin, M., Nazimuddin, K., Mollah, A. S., Siddiqui, M. N. I., Hassan, K. A. A., Ferdous, H., Rahman, M., Ashrafuzzaman, S., Sobhan, M. J., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_545_17 · Cited by 5
Safety of Blood Glucose Response Following Exercise Training After Bariatric Surgery
Proulx, É., Auclair, A., Piché, M., Harvey, J., Pettigrew, M., Biertho, L. D., Marceau, S., & Poirier, P. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3449-8 · Cited by 4
False paraprotein-induced hypoglycemia in the measurement of glucose by the hexokinase method
Bossard, V., Sauvageon, Y., Fraissinet, F., Dreyfus, B., Thuillier, R., & Hauet, T. (2019) · Annales de biologie clinique · doi:10.1684/abc.2019.1465 · Cited by 5
Singh, A. K., Talwalkar, P., Ahluwalia, A. I., Modi, K. D., & Saboo, B. (2018) · PubMed · Cited by 5
Biester, T., Berge, T. V. D., Bendtsen, L. Q., Bendtsen, M. D., Rathor, N., Danne, T., & Haahr, H. L. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13026 · Cited by 4
Jermendy, G., Kecskés, Á., & Nagy, A. C. (2021) · Medicina · doi:10.3390/medicina57020167 · Cited by 6
“9 mmol/L was named an alert value [34,35].”
BackgroundFalla autonómica asociada a hipoglucemia
Houssay, S., Recalde, M., Rey, M. G., García, C., Urdaneta, R., Huber, F., Flores, C. L. U., Domínguez, C., & Nader, E. (2021) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v55i2.473 · Cited by 4
Evolving Classification Rules for Predicting Hypoglycemia Events
de la Cruz, M., Cervigón, C., Alvarado, J., Botella-Serrano, M., & Hidalgo, J. I. (2022) · IEEE Congress on Evolutionary Computation (CEC) · doi:10.1109/cec55065.2022.9870380 · Cited by 4
“Hypoglycemia is identified when the blood glucose level falls below 70 mg/dL [1], but as a reference of possible hypoglycemia states, the American Diabetes Association (ADA) work-group has proposed a classification with five different grades, from Severe Hypoglycemia to Pseudo-hypoglycemia [2], [3].”
BackgroundHypoglycaemia and CV risk: Perceptions and reality
Ghosal, S., & Sinha, B. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.10.021 · Cited by 4
Patton, S. R., DeLurgio, S. A., & Clements, M. A. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0061 · Cited by 4
Harris, C. J., Forst, T. M., Heise, T., Plum‐Mörschel, L., Watkins, E., Zhang, Q., Fan, L., Garhyan, P., & Pørksen, N. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0414 · Cited by 4
Insulin Therapy in Gestational Diabetes
Stoian, A. P., Stoica, R. A., & Ștefan, S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.84569 · Cited by 5
Eleftheriadou, I., Didangelos, T., Pappas, A. C., Anastasiou, E., Vasilopoulos, C., Zoupas, C., Manes, C., Tsatsoulis, A. A., Benroubi, M., Pangalos, E., et al. (2019) · HORMONES · doi:10.1007/s42000-019-00153-1 · Cited by 5
“Patients with poor glycemic control usually report hypoglycemia symptoms at higher glucose levels than patients with tighter glycemic control [11].”
BackgroundMyat, A., Redwood, S. R., Arri, S. S., Gersh, B. J., Bhatt, D. L., & Marber, M. S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00635-6 · Cited by 5
“There were no symptomatic episodes of hypoglycaemia recorded for any participant throughout the course of the trial [26].”
BackgroundSchübert, H., Müller, U. A., Kramer, G., Muller, N., Heller, T., Kloos, C., & Kuniß, N. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0631-8813 · Cited by 7
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
Carter, K., Cheung, W., Hutchings, H. A., Fegan, G., Holland, G., Luzio, S. D., Dunseath, G. J., Hiles, S., Marques-Jones, S., Gregory, J. W., et al. (2025) · Efficacy and Mechanism Evaluation · doi:10.3310/fqln7416 · Cited by 4
Wilmot, E. G., Ajjan, R., Cheah, Y. S., Choudhary, P., CRANSTON, I. C., Elliott, R. A., Evans, M. L., Iqbal, A., Kamaruddin, S., Barnard-Kelly, K. D., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090154 · Cited by 6
DEVORE, M. H., Hepworth, E., Agni, A., Ye, W., Amiel, S. A., Fisher, S. J., & Lin, Y. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0126 · Cited by 3
Rahman, M. H., Selim, S., Afsana, F., Hoque, M. A., Saifuddin, M., Alam, M. S., Sharifuzzaman, M., Tareq, M. A. H., Hasan, M. N., Kamrul-Hasan, A. B. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70343 · Cited by 5
Qudah, J. A., Beni, N. D., Ibrahim, N., Khader, S., Dempsey, L., & Butler, A. E. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1699384 · Cited by 4
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“Mechanistically, hypoglycemia-induced neuronal injury involves neuronal energy failure, excitotoxicity, and oxidative stress, ultimately leading to mitochondrial dysfunction and inflammatory activation in vulnerable brain regions [23].”
Costes y efectividad de un detector de tendencias glucémicas en pacientes con diabetes mellitus
García‐Mochón, L., Lima, A. O. D. L., & Espín, J. (2014) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.11.001 · Cited by 4
Ringholm, L., Ásbjörnsdóttir, B., Andersen, H. U., Damm, P., & Mathiesen, E. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-56440-1_30 · Cited by 3
Nattero‐Chávez, L., de la Villa, E. D. L. C., Pascual, E. L., Cebada, A. B., Gracia, T. R., Tobar, A. Q., Moñino, M. L., Rodríguez, C. S., Izquierdo, A., Escobar-Morreale, H. F., et al. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241288789 · Cited by 4
Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Pathan, M. F., Akter, N., Mustari, M., Saifuddin, M., Sharifuzzaman, M., Rahman, M. M., Ripon, M., Mohiuddin, S. M., Kamrul-Hasan, A. B. M., Hannan, M. A., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1542946 · Cited by 7
Paul, S. K., Agbeve, J., Maggs, D. G., & Best, J. H. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12269 · Cited by 3
“Hypoglycemia has been well recognized as an adverse consequence of treatment with some antidiabetes therapies in patients with type 2 diabetes mellitus (T2DM).(1) Several clinical and epidemiological studies have demonstrated hypoglycemia as a common problem in insulintreated patients with T2DM, and hypoglycemia has b…”
BackgroundNishimura, H., Iizuka, K., & Takeda, J. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0544 · Cited by 3
Hypoglycaemia, emergency care and diabetes mellitus
Moheet, A. A., & Seaquist, E. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.67 · Cited by 3
Self-citationMelidonis, A. J., Kamaratos, A. V., Angelidi, A. M., Thomakos, P., Vrakas, S., Bakalis, J., Fousteris, E., & Iraklianou, S. A. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0309 · Cited by 6
Maran, A., Crepaldi, C., Piccolo, F. D., Macdonald, I. A., Zarantonello, L., Avogaro, A., & Amodio, P. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0041-1 · Cited by 3
Feeding Insulin: Adverse Consequences With Tight Glycemic Control
Carlson, J. A., Craven, K., & Kolasa, K. M. (2015) · Nutrition Today · doi:10.1097/nt.0000000000000095 · Cited by 3
“These elements affect not only family and social relationship but also daily activities such as driving and being able to function in the world of work.(27,28)”
BackgroundPalmer, C. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000525719.99231.41 · Cited by 5
“The ADA defi nes hypoglycemia as a blood glucose level less than 70 mg/dL, a value low enough to alert patients and providers to a potential complication, but high enough to not cause severe symptoms.(21) Hypoglycemia can be categorized on a spectrum from mild (self-treated) to severe (requiring assistance from anothe…”
Flash Glucose Monitoring: A Patient's and Clinician's Caveats and Concerns
Argento, N. B. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0216 · Cited by 3
Luo, Y., Wang, X., Ni, W.-J., Ding, B., Xu, X., Ye, L., Ma, J., & Zhu, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0502-5 · Cited by 4
Diabetes in the Workplace: the Hazards of Hypoglycemia
Gerbo, R., Jin, C. F., & Clark, K. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1234-2 · Cited by 5
Hypoglycemic risk exposures in relation to low serum glucose values in ambulatory patients
Abusamaan, M. S., Marzinke, M. A., Ashok, A., Carroll, K. C., Lane, K. L., Jeun, R., Moseley, K. F., Carson, K. A., & Mathioudakis, N. N. (2020) · Medicine · doi:10.1097/md.0000000000018679 · Cited by 3
“There is no absolute BGV that defines severe hypoglycemia, but this is generally considered to be a level at which severe cognitive impairment occurs prompting the need for third-party assistance for recovery.([2]) A challenge for clinical laboratories and health systems is identifying a BGV in a general population th…”
BackgroundBayrasheva, V. K., Pchelin, I. Y., Dobronravov, V., Babenko, A. Y., Чефу, С. Г., Shatalov, I. S., Vasilkova, V., Hudiakova, N. V., Ivanova, A. N., Andoskin, P. A., et al. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000220 · Cited by 3
“9 mmol/L with or without symptoms (27).”
Person-Centered Medication Therapy for Diabetes in Older Adults: A Practical Review
Wilson, E. (2021) · Journal of Gerontological Nursing · doi:10.3928/00989134-20210908-02 · Cited by 3
Attitudes to driving among patients with diabetes mellitus in Punjab (ADD-Punjab study)
Waris, A., Jose, R., Mathew, N., & Jacob, J. J. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.11.007 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Sinclair, J. E., Austin, M., Leduc, S., Dionne, R., Froats, M., Marchand, J., & Vaillancourt, C. (2022) · Prehospital Emergency Care · doi:10.1080/10903127.2022.2137863 · Cited by 4
“, too much insulin, skipped a meal, alcohol ingestion), nor were we able to capture all morbidities and clinical syndromes previously linked with hypoglycemia such as severe liver disease, renal insufficiency, or malnutrition (37).”
Background
Metadata
- Authors
- Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R.
- Affiliations
- University of Minnesota (US)
- The Frist Clinic, Nashville, Tennessee;
- Mid-America Diabetes Associates, Wichita, Kansas; the
- Washington University in St. Louis (US)
- University of Tennessee Health Science Center (US)
- Park Nicollet Clinic (US)
- University of Sheffield (GB)
- University of South Florida (US)
- Boston University (US)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Seaquist, Elizabeth R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1384-1395
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631867
- OpenAlex
- W2109416725
- Cited by
- 1,389
- References
- 141
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 62 · 2023: 66 · 2022: 92 · 2021: 127 · 2020: 119 · 2019: 149 · 2018: 148 · 2017: 151 · 2016: 129 · 2015: 129 · 2014: 92 · 2013: 33
- FWCI
- 100.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, diabetes mellitus, hypoglycemia definition, hypoglycemia prevention, long-term outcomes, patient counseling, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemia, Societies, Medical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.